Review
Oncology
Shuang Huang, Gang Zheng, Kai Yang
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of neoadjuvant PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in malignant solid tumors. The results showed that the addition of CTLA-4 inhibitors did not significantly improve overall response rate and survival outcomes. However, there was an increased risk of grade 3-4 adverse events with the combination therapy. More large-scale and multicenter randomized controlled trials are needed to obtain more reliable results.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Satoshi Muto, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
Summary: The proportions of CTLA-4(+) regulatory T cells to CD8 T cells and CTLA-4(+) cells in CD8 T cells were found to be irrelevant to the PD-L1 TPS in NSCLC patients.
ANTICANCER RESEARCH
(2021)
Review
Oncology
Alberto Carretero-Gonzalez, Irene Otero, David Lora, Lucia Carril-Ajuria, Daniel Castellano, Guillermo de Velasco
Summary: The study examines the benefits and risks of adding ICIs to standard of care, finding that adding ICIs can prolong survival with no early detrimental effect. Results show that ICIs arm has better PFS, OS, and ORR compared to SOC, although also associated with a slight increase in high-grade adverse events.
Article
Chemistry, Multidisciplinary
Yoshihide Suzuki, Keisuke Ichinohe, Akihiro Sugawara, Shinya Kida, Shinya Murase, Jing Zhang, Osamu Yamada, Toshio Hattori, Yoshiteru Oshima, Haruhisa Kikuchi
Summary: In this study, novel immune checkpoint inhibitors with enhanced potency were developed through modifications of an existing unnatural pentacyclic compound. These inhibitors showed the ability to suppress both CTLA-4 and PD-L1 gene expression and protein expression, making them the first reported dual small-molecule inhibitors of CTLA-4 and PD-L1.
FRONTIERS IN CHEMISTRY
(2021)
Review
Oncology
Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, Francesco Gelsomino, Andrea Ardizzoni
Summary: For advanced NSCLC patients with PD-L1 expression >50%, a combination of chemotherapy and immunotherapy is preferred over immunotherapy alone due to better efficacy outcomes and less safety concerns. However, there is a significant difference in early progression-free survival rates between the two strategies, with more patients experiencing early disease progression with immunotherapy alone.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Immunology
Yinan Yu, Xueying Jin, Xiaoling Zhu, Yan Xu, Wei Si, Jianguo Zhao
Summary: Through meta-analysis, the study found that PD-1/PD-L1 immune checkpoint inhibitors combined with chemotherapy can significantly improve the progression-free survival of patients with metastatic triple negative breast cancer, but only significantly improve the overall survival in PD-L1 positive population. In addition, the incidence of immune-related adverse events is significantly higher in the ICIs group compared to chemotherapy, which needs to be taken seriously.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Chemistry, Analytical
Pei Wang, Longfei Tang, Bohui Zhou, Liangfen Cheng, Robert Chunhua Zhao, Juan Zhang
Summary: Immune checkpoints are a series of molecules that regulate the degree of immune activation, including PD-1/PD-L1, CTLA-4, LAG-3, and others. Immune checkpoint therapy is considered to be a safer and more effective treatment for tumor immunotherapy compared to conventional therapy. The analysis of immune checkpoints is crucial for immunotherapy medication, treatment, and prognosis evaluation.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY
(2022)
Article
Agriculture, Dairy & Animal Science
Ilaria Porcellato, Samanta Mecocci, Chiara Brachelente, Katia Cappelli, Federico Armando, Alessia Tognoloni, Elisabetta Chiaradia, Valentina Stefanetti, Luca Mechelli, Marco Pepe, Rodolfo Gialletti, Benedetta Passeri, Alessandro Ghelardi, Elisabetta Razzuoli
Summary: The study investigated the expression of PD-L1 and CTLA-4 in penile tumors of horses, particularly in malignant squamous cell carcinomas. Results showed that these molecules are not frequently expressed in equine penile tumors, suggesting limited efficacy of ICI in treating these tumors.
Article
Medicine, Research & Experimental
Youliang Zhao, Changfu Hao, Meng Li, Yaqian Qu, Yonghua Guo, Xuedan Deng, Huifang Si, Wu Yao
Summary: This study demonstrates the potential value of immune checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors, in the treatment of silica-induced pulmonary fibrosis. The findings suggest that these inhibitors can modulate immune system disruption caused by silica exposure and provide new ideas for the treatment of fibrosis-related diseases.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Oncology
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime
Summary: Immune checkpoint inhibitors have shown therapeutic benefits in solid cancers and some hematological malignancies, but predicting treatment response remains challenging. Studies on the dynamics of the immune system and tumor under immune checkpoint blockade have revealed mechanisms of action and adaptive resistance to these therapeutic agents.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Akhilesh Mishra, Kuldeep Gupta, Dhiraj Kumar, Gabriela Lofland, Ajay Kumar Sharma, Lilja B. Solnes, Steven P. Rowe, Patrick M. Forde, Martin G. Pomper, Edward W. Gabrielson, Sridhar Nimmagadda
Summary: This study investigated the relationship between PD-L1 expression and therapy-induced changes in cancer using a peptide-based PD-L1 imaging agent, [F-18]DK222, in humanized mouse models. The results showed that [F-18]DK222-PET has potential as a non-invasive tool for monitoring the effects of immunotherapy on tumors, detecting variable PD-L1 expression, quantifying therapy-induced changes, and differentiating the impact of different therapies on tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Wen Kou, Yan Yan Lin, Fei Su, Yue Xiang, Hui Qiao, Xin'An Wu, Xiao-Ming Hou
Summary: This study aimed to evaluate the impact of a pharmaceutical care program in reducing adverse events in NSCLC patients receiving ICIC therapies. The program, which involved pharmacist interventions, optimized drug therapy and resulted in significant decreases in adverse events such as nausea, constipation, diarrhea, and myelosuppression.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu, Quan Cheng
Summary: The regulatory mechanisms of PD-L1 and CTLA-4 play a crucial role in immunotherapy, and understanding their interactions can help improve patients' treatment responses and clinical care.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Zhaodan Xin, Liting You, Feifei Na, Jin Li, Min Chen, Jiajia Song, Ling Bai, Jie Chen, Juan Zhou, Binwu Ying
Summary: In this study, the researchers identified several immunogenetic variants associated with immune-related adverse events (irAEs) and irAEs-free survival in patients treated with PD-1/PD-L1 inhibitors, which could serve as potential predictive biomarkers.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Xiao Hu, Jin Ren, Qianfei Xue, Rumei Luan, Dongyan Ding, Jie Tan, Xin Su, Junling Yang
Summary: Immune checkpoint inhibitors have a significant role in the treatment of non-small cell lung cancer. However, immune-related adverse events, particularly checkpoint inhibitor pneumonitis, limit their clinical application. This study summarizes the occurrence, characteristics, pathogenesis, risk factors, and management of checkpoint inhibitor pneumonitis to enhance our understanding and guide treatment.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Yuting Jiang, Chengdi Wang, Shengtao Zhou
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2020)
Article
Biochemistry & Molecular Biology
Jun Shao, Chengdi Wang, Pengwei Ren, Yuting Jiang, Panwen Tian, Weimin Li
BIOSCIENCE REPORTS
(2020)
Article
Biochemistry & Molecular Biology
Kang Zhang, Xiaohong Liu, Jun Shen, Zhihuan Li, Ye Sang, Xingwang Wu, Yunfei Zha, Wenhua Liang, Chengdi Wang, Ke Wang, Linsen Ye, Ming Gao, Zhongguo Zhou, Liang Li, Jin Wang, Zehong Yang, Huimin Cai, Jie Xu, Lei Yang, Wenjia Cai, Wenqin Xu, Shaoxu Wu, Wei Zhang, Shanping Jiang, Lianghong Zheng, Xuan Zhang, Li Wang, Liu Lu, Jiaming Li, Haiping Yin, Winston Wang, Oulan Li, Charlotte Zhang, Liang Liang, Tao Wu, Ruiyun Deng, Kang Wei, Yong Zhou, Ting Chen, Johnson Yiu-Nam Lau, Manson Fok, Jianxing He, Tianxin Lin, Weimin Li, Guangyu Wang
Article
Computer Science, Artificial Intelligence
Xiuyuan Xu, Chengdi Wang, Jixiang Guo, Yuncui Gan, Jianyong Wang, Hongli Bai, Lei Zhang, Weimin Li, Zhang Yi
MEDICAL IMAGE ANALYSIS
(2020)
Article
Oncology
Chengdi Wang, Yuxuan Wu, Jingwei Li, Pengwei Ren, Ya Gou, Jun Shao, Yaojie Zhou, Xue Xiao, Paierhati Tuersun, Dan Liu, Li Zhang, Weimin Li
ANNALS OF TRANSLATIONAL MEDICINE
(2020)
Article
Microbiology
Jing-wen Lin, Chao Tang, Han-cheng Wei, Baowen Du, Chuan Chen, Minjin Wang, Yongzhao Zhou, Ming-xia Yu, Lu Cheng, Suvi Kuivanen, Natacha S. Ogando, Lev Levanov, Yuancun Zhao, Chang-ling Li, Ran Zhou, Zhidan Li, Yiming Zhang, Ke Sun, Chengdi Wang, Li Chen, Xia Xiao, Xiuran Zheng, Sha-sha Chen, Zhen Zhou, Ruirui Yang, Dan Zhang, Mengying Xu, Junwei Song, Danrui Wang, Yupeng Li, ShiKun Lei, Wanqin Zeng, Qingxin Yang, Ping He, Yaoyao Zhang, Lifang Zhou, Ling Cao, Feng Luo, Huayi Liu, Liping Wang, Fei Ye, Ming Zhang, Mengjiao Li, Wei Fan, Xinqiong Li, Kaiju Li, Bowen Ke, Jiannan Xu, Huiping Yang, Shusen He, Ming Pan, Yichen Yan, Yi Zha, Lingyu Jiang, Changxiu Yu, Yingfen Liu, Zhiyong Xu, Qingfeng Li, Yongmei Jiang, Jiufeng Sun, Wei Hong, Hongping Wei, Guangwen Lu, Olli Vapalahti, Yunzi Luo, Yuquan Wei, Thomas Connor, Wenjie Tan, Eric J. Snijder, Teemu Smura, Weimin Li, Jia Geng, Binwu Ying, Lu Chen
Summary: This study utilized an integrative approach to analyze mutations of the SARS-CoV-2 virus, identifying 35 recurrent variants of clinical importance, with one variant associated with severe clinical phenotypes. The findings suggest that mutations in Nsp1 may have implications for molecular diagnostics and drug design.
CELL HOST & MICROBE
(2021)
Article
Engineering, Biomedical
Guangyu Wang, Xiaohong Liu, Jun Shen, Chengdi Wang, Zhihuan Li, Linsen Ye, Xingwang Wu, Ting Chen, Kai Wang, Xuan Zhang, Zhongguo Zhou, Jian Yang, Ye Sang, Ruiyun Deng, Wenhua Liang, Tao Yu, Ming Gao, Jin Wang, Zehong Yang, Huimin Cai, Guangming Lu, Lingyan Zhang, Lei Yang, Wenqin Xu, Winston Wang, Andrea Olevera, Ian Ziyar, Charlotte Zhang, Oulan Li, Weihua Liao, Jun Liu, Wen Chen, Wei Chen, Jichan Shi, Lianghong Zheng, Longjiang Zhang, Zhihan Yan, Xiaoguang Zou, Guiping Lin, Guiqun Cao, Laurance L. Lau, Long Mo, Yong Liang, Michael Roberts, Evis Sala, Carola-Bibiane Schonlieb, Manson Fok, Johnson Yiu-Nam Lau, Tao Xu, Jianxing He, Kang Zhang, Weimin Li, Tianxin Lin
Summary: An automated deep-learning pipeline was developed for standardizing chest X-ray images, visualizing lesions, and diagnosing diseases, which can identify viral pneumonia caused by COVID-19, assess its severity, and distinguish it from other types of pneumonia. The system showed high discriminative abilities across different types of pneumonia and performed comparably to senior radiologists, indicating its potential to support clinical decision-making and facilitate early intervention.
NATURE BIOMEDICAL ENGINEERING
(2021)
Article
Oncology
Chengdi Wang, Jingwei Li, Qiran Zhang, Jiayang Wu, Yuxuan Xiao, Lujia Song, Hanlin Gong, Yalun Li
Summary: The study found that ICI therapy has significant survival benefits in both NSCLC and SCLC patients compared to chemotherapy, with better disease control and survival benefits. In SCLC patients, first-line immunotherapy showed advantages, while in NSCLC patients, combination therapy with ICIs and SOC is recommended.
Article
Oncology
Chengdi Wang, Jun Shao, Junwei Lv, Yidi Cao, Chaonan Zhu, Jingwei Li, Wei Shen, Lei Shi, Dan Liu, Weimin Li
Summary: This study successfully predicted the histologic subtype classification and survival of lung adenocarcinoma diagnosed through CT images using deep learning and radiomics networks. The deep radiomics algorithm achieved an accuracy of 0.8776 in the 2-category classification and 0.8061 in the 3-category classification in internal validation.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Health Care Sciences & Services
Peiyi Li, Chenyang Zhang, Shuanliang Gao, Yanbo Zhang, Xiaolong Liang, Chengdi Wang, Tao Zhu, Weimin Li
Summary: This study found that middle-aged and older adults who use the internet have a reduced risk of developing chronic diseases versus those who do not use the internet. The risk of some chronic diseases decreases with increasing frequency of internet use.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Jingwei Li, Yun Zhou, Jiechao Ma, Qin Zhang, Jun Shao, Shufan Liang, Yizhou Yu, Weimin Li, Chengdi Wang
Summary: COVID-19 may lead to long-term symptoms in multiple systems, referred to as long COVID, and can impact patients of varying severity. This comprehensive review highlights the epidemiology, impact of vaccinations, organ-specific sequelae, pathophysiological mechanisms, and multidisciplinary management strategies of long COVID, with emphasis on psychological and psychosomatic factors. Current diagnostic and therapeutic strategies are inadequate, and further clinical trials are needed to validate existing hypotheses.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Chengdi Wang, Qiuxiao Yu, Tingting Song, Zhoufeng Wang, Lujia Song, Ying Yang, Jun Shao, Jingwei Li, Yinyun Ni, Ningning Chao, Li Zhang, Weimin Li
Summary: An investigation into the immune landscape is crucial for immunotherapy strategies and predicting clinical responses in non-small-cell lung cancer patients. Using single-cell RNA sequencing, researchers have identified immune signature differences between lung adenocarcinoma and lung squamous cell carcinoma, the two major subtypes of NSCLC. They found that cytotoxic and effector T and NK cells, as well as distinct macrophage subtypes, play central roles in the immune microenvironment heterogeneity between the two subtypes. This comprehensive depiction of immune heterogeneity could aid in personalized treatment design.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Article
Oncology
Jun Shao, Jingwei Li, Lujia Song, Qiuyao He, Yuxuan Wu, Linhui Li, Dan Liu, Chengdi Wang, Weimin Li
Summary: The number of brain metastases is an important factor affecting the prognosis of lung cancer patients, with EGFR-mutated patients showing better survival outcomes. Extracranial metastases and chemotherapy are independent prognostic factors.
Review
Biochemistry & Molecular Biology
Chengdi Wang, Zhoufeng Wang, Guangyu Wang, Johnson Yiu-Nam Lau, Kang Zhang, Weimin Li
Summary: Since the first description of a coronavirus-related pneumonia outbreak in December 2019, the virus SARS-CoV-2 has evolved into a pandemic, affecting over 100 million people globally. This review summarized the current knowledge in epidemiology, virology, diagnosis, treatment, and vaccine development, providing specific dates for key developments. The world is working together to combat this pandemic, highlighting the rapid evolution of research and development in these areas.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)